If you are choosing a probiotic specifically for vaginal health, the strain matters more than the biggest CFU number on the bottle. This ranking is based primarily on the strength of human clinical evidence, with extra weight given to randomized controlled trials involving bacterial vaginosis, recurrent BV, vulvovaginal candidiasis, and restoration of Lactobacillus-dominant vaginal flora.
The strongest evidence right now is concentrated in a relatively small number of specific Lactobacillus strains, not probiotics as a broad category.
If I had to rank one probiotic strain first for vaginal health, Lactobacillus crispatus CTV-05 would be it, because it has unusually strong strain-specific randomized trial data for recurrent BV. In the NIH-funded Lactin-V trial published in the New England Journal of Medicine, 228 women were randomized after completing vaginal metronidazole treatment. BV recurred by week 12 in 30% of women receiving L. crispatus CTV-05 compared with 45% receiving placebo, with the benefit continuing through week 24.
Limitation
Lactin-V is a specific live biotherapeutic formulation, so you cannot assume that an over-the-counter product containing a different L. crispatus strain will produce the same result. If recurrent bacterial vaginosis is the reason you are researching L. crispatus, this is the strain that makes the overall concept particularly compelling.
Lacticaseibacillus rhamnosus GR-1 has one of the longest histories of human vaginal probiotic research. It is usually studied together with RC-14, so I would not pretend that we know exactly how much benefit comes from GR-1 independently, but the combination has produced some impressive results.
In a randomized, double-blind trial of 125 women with BV, participants received oral metronidazole plus either GR-1 and RC-14 or placebo. Among those returning for follow-up, 88% of the probiotic group met the study's cure criteria compared with 40% of the antibiotic plus placebo group at day 30.
Limitation
A label that says only "Lactobacillus rhamnosus" is not necessarily giving you the GR-1 strain used in these trials.
Limosilactobacillus reuteri RC-14 ranks immediately behind GR-1 because these strains are essentially a research partnership in vaginal probiotic studies.
Another randomized, double-blind trial evaluated GR-1 and RC-14 after a single dose of tinidazole in 64 women with BV. At day 28, BV cure was reported in 87.5% of the probiotic group compared with 50% of the placebo group. Normal vaginal microbiota by Nugent score was also more common in the probiotic group.
Not every trial has been positive. A later randomized study involving 126 Chinese women found no improvement in 30-day or 90-day BV cure when GR-1 and RC-14 were added to vaginal metronidazole.
That is exactly why I recommend these strains as a reasonable adjunct rather than telling patients that they are a guaranteed treatment.
Lactobacillus acidophilus has been used in vaginal probiotic research for decades, but the exact strain still matters. Lactobacillus acidophilus LA-5 has direct randomized clinical data in women with vulvovaginal candidiasis.
A triple-blinded randomized trial involving 80 women compared an oral probiotic containing LA-5 with fluconazole. At the earlier follow-up there was no statistically significant difference in negative cultures, but by approximately two months fluconazole performed better for culture clearance and several clinical outcomes.
That does not make LA-5 a replacement for fluconazole.
Lactobacillus gasseri LbV 150N makes the list because it has human randomized evidence as part of a four-strain vaginal-health formulation, although its evidence is less direct than CTV-05, GR-1, or RC-14.
A randomized controlled pilot trial gave women with BV metronidazole followed by a yogurt drink containing L. crispatus LbV 88, L. gasseri LbV 150N, L. jensenii LbV 116, and L. rhamnosus LbV96. After four weeks, none of 17 women in the probiotic group met BV criteria compared with 6 of 17 in the control group.
A later meta-analysis examining this same four-strain combination found improved Nugent scores compared with placebo across randomized trials.
Limitation
I still think it belongs on the list because L. gasseri is biologically relevant to vaginal flora, and this exact strain has actually been included in controlled human research.
If I were choosing a probiotic specifically for vaginal health, I would look for the exact strain designation, not simply the species name. I would prioritize:
A larger CFU number does not automatically mean a better vaginal probiotic.
The CDC's current guidance remains more conservative. Its 2021 guidelines do not consider probiotics established replacement or adjunctive therapy for BV or proven treatment for vulvovaginal candidiasis. I think the newer strain-specific data justify a somewhat more progressive position, particularly for recurrent BV. I am comfortable discussing probiotics as an adjunct while still treating an active infection appropriately.
Lactobacillus crispatus CTV-05 has some of the strongest strain-specific human evidence for reducing recurrent bacterial vaginosis after standard treatment.
The evidence for GR-1 and RC-14 is promising but not perfectly consistent across populations and studies.
GR-1 is most convincing when paired with RC-14 because much of the positive clinical evidence studied the two strains together.
I would consider Lactobacillus acidophilus LA-5 an interesting vaginal-health strain, but I would not use it instead of established antifungal treatment for an active yeast infection.
The clinical evidence for L. gasseri LbV 150N comes primarily from multi-strain formulations, so we cannot say that LbV 150N alone produced the observed benefit.